TheraCyte Cell Encapsulation System IDE Slated For Second Quarter
This article was originally published in The Gray Sheet
TheraCyte, Inc. plans to file an investigational device exemption with FDA during the second quarter for a Phase I study intended to evaluate the TheraCyte encapsulated cell technology implant system.
You may also be interested in...
Genzyme General plans to spin off its surgical products business into a separately traded company by the third quarter of 1999 in order to accelerate growth in both businesses, the Cambridge, Massachusetts-based firm announced March 4 in reporting 1998 year-end results.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.